KR102337919B1 - Cosmetic composition containing yellow chlorella extract - Google Patents
Cosmetic composition containing yellow chlorella extract Download PDFInfo
- Publication number
- KR102337919B1 KR102337919B1 KR1020190164068A KR20190164068A KR102337919B1 KR 102337919 B1 KR102337919 B1 KR 102337919B1 KR 1020190164068 A KR1020190164068 A KR 1020190164068A KR 20190164068 A KR20190164068 A KR 20190164068A KR 102337919 B1 KR102337919 B1 KR 102337919B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- skin
- composition
- chlorella
- yellow
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 241000195649 Chlorella <Chlorellales> Species 0.000 title claims abstract description 67
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 239000002537 cosmetic Substances 0.000 title claims abstract description 29
- 210000003491 skin Anatomy 0.000 claims abstract description 66
- 230000014509 gene expression Effects 0.000 claims abstract description 32
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 21
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 19
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 230000008591 skin barrier function Effects 0.000 claims abstract description 7
- 230000037380 skin damage Effects 0.000 claims abstract description 7
- 210000004927 skin cell Anatomy 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 30
- 239000008103 glucose Substances 0.000 claims description 30
- 229930091371 Fructose Natural products 0.000 claims description 29
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 29
- 239000005715 Fructose Substances 0.000 claims description 28
- 229920001542 oligosaccharide Polymers 0.000 claims description 28
- 150000002482 oligosaccharides Chemical class 0.000 claims description 28
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 23
- 201000004624 Dermatitis Diseases 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 9
- -1 serum Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010015150 Erythema Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 4
- 102000004363 Aquaporin 3 Human genes 0.000 claims description 4
- 108090000991 Aquaporin 3 Proteins 0.000 claims description 4
- 108090000600 Claudin-1 Proteins 0.000 claims description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 206010043255 Tendonitis Diseases 0.000 claims description 4
- 231100000321 erythema Toxicity 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010014190 Eczema asteatotic Diseases 0.000 claims description 3
- 208000029648 Eczematous Skin disease Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 101100173783 Oryza sativa subsp. japonica UBP5 gene Proteins 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 14
- 230000006872 improvement Effects 0.000 abstract description 13
- 101710128038 Hyaluronan synthase Proteins 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 210000002510 keratinocyte Anatomy 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 230000004069 differentiation Effects 0.000 abstract description 5
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 abstract description 3
- 108090000695 Cytokines Proteins 0.000 abstract description 3
- 101150063233 FLG gene Proteins 0.000 abstract description 2
- 229960002737 fructose Drugs 0.000 description 20
- 239000013642 negative control Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 102100028314 Filaggrin Human genes 0.000 description 5
- 101710088660 Filaggrin Proteins 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 102000010637 Aquaporins Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004162 Claudin-1 Human genes 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001493760 Chlorellaceae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 101150089672 HAS3 gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/606—Fructose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/61—Glucose, Dextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
황색 클로렐라 추출물 및 당류를 포함하는 화장료 조성물에 관한 것이다. 일 양상에 따른 황색 클로렐라 추출물 및 당류를 포함하는 화장료 조성물에 의하면, 피부 세포에서 히알루론산 합성 효소(HAS3), 각질형성 세포 분화 유전자인 FLG 유전자의 발현을 증가시켜 피부에 보습효과 및 피부 장벽 개선 효과가 나타나며, 염증 사이토카인 IL-1β 발현을 현저하게 감소시켜 피부 손상, 피부 상태, 또는 염증성 질환의 예방, 개선 또는 치료에 유용하게 사용할 수 있는 효과가 있다. It relates to a cosmetic composition comprising a yellow chlorella extract and saccharides. According to a cosmetic composition comprising a yellow chlorella extract and saccharides according to an aspect, the expression of hyaluronic acid synthase (HAS3) and FLG gene, which is a keratinocyte differentiation gene, is increased in skin cells, thereby moisturizing the skin and improving the skin barrier. appears, and significantly reduces the expression of the inflammatory cytokine IL-1β, thereby having an effect that can be usefully used for the prevention, improvement or treatment of skin damage, skin condition, or inflammatory disease.
Description
황색 클로렐라 추출물 및 당류를 포함하는 화장료 조성물에 관한 것이다. It relates to a cosmetic composition comprising a yellow chlorella extract and saccharides.
염증은 해로운 주위 환경, 즉 세균과 같은 외부 이물질의 침입과 기계적 손상으로부터 생체를 보호하는 생리적인 반응인데, 과도한 염증 반응 또한 피부 손상의 주요 원인이다. 염증이 발생하면, 여러 종류의 다핵형 백혈구(PMNs)와 면역 물질의 증가를 초래하고, 이들 세포들은 염증성 세포 산물인 다양한 종류의 단백질 분해효소와 사이토카인(cytokine)을 분비하게 된다. 이후 이들의 작용은 인접해 있는 조직 세포와 비 조직세포 성분들에게도 해로운 손상을 일으키고, 만성염증의 심각한 조직 손상을 가져올 수 있다. 또한, 결합 조직의 손상은 피부의 탄력을 감소시켜 주름의 원인이 될 뿐 아니라 나아가 세포의 재생 및 증식에도 나쁜 영향을 미치게 되어 빠른 피부 손상을 초래하게 된다.Inflammation is a physiological reaction that protects the living body from the intrusion of foreign substances such as bacteria and mechanical damage from the harmful surrounding environment, that is, excessive inflammatory reaction is also a major cause of skin damage. When inflammation occurs, various types of polynuclear leukocytes (PMNs) and immune substances increase, and these cells secrete various types of proteolytic enzymes and cytokines, which are inflammatory cell products. After that, their action may cause harmful damage to adjacent tissue cells and non-tissue cell components, and may lead to serious tissue damage of chronic inflammation. In addition, damage to the connective tissue reduces the elasticity of the skin and causes wrinkles, and furthermore, it adversely affects the regeneration and proliferation of cells, resulting in rapid skin damage.
기능성 화장품은 피부노화를 지연시켜 피부의 주름개선에 도움을 주는 제품, 자외선 및 외부환경으로부터 피부를 보호하는 제품, 또는 피부의 미백에 도움을 주는 제품을 포함할 수 있다. 이러한 기능성 화장품의 개발을 위해서는 피부 내에서 생리적으로 효능을 나타낼 수 있으면서 동시에 안전한 기능성 원료의 개발이 선행되어야 한다.Functional cosmetics may include products that help improve skin wrinkles by delaying skin aging, products that protect skin from UV rays and external environments, or products that help skin whitening. For the development of such functional cosmetics, the development of functional raw materials that are physiologically effective in the skin and at the same time safe should be preceded.
클로렐라(Chlorella)는 녹조식물 클로렐라과에 속하는 담수조류의 일종으로서, 녹민물·습지 등에서 흔히 볼 수 있으며 광합성에 의해 성장, 증식하는 독립영양성과 유기탄소원을 이용하여 증식하는 종속영양성의 두 가지 생육 성질을 갖는 단세포 식물로서 엽록소(chlorophyll a, b)를 다량 함유하고 있다. 상기 클로렐라는 많은 효능이 보고되고 있는데, 일련의 연구 결과들을 통해 클로렐라 추출물은 미생물이나 바이러스 감염(Thnaka et al. , 1986; Hasegawa et al. , 1990)과 각종 암 생성(Morimoto et al. , 1995; Konishi et al. , 1985)으로부터 보호할 수 있음이 보고되었으나, 이는 주로 녹색 클로렐라 추출물에 대한 것이고, 황색 클로렐라 추출물에 대해서 구체적인 피부 보호 효과 혹은 피부 항염증 효과에 대해서는 알려지지 않았다.Chlorella (Chlorella) are two growth properties of a type of freshwater algae belonging to Chlorophyta chlorellaceae, commonly seen in melted fresh water, wetlands and dependent for growth and by photosynthesis using the growth, proliferation independent nutritional and an organic carbon source for nutrient It is a single-celled plant that contains a large amount of chlorophyll (chlorophyll a, b). The chlorella has been reported to have many effects, and through a series of studies, the chlorella extract is used for microbial or viral infection (Thnaka et al., 1986; Hasegawa et al., 1990) and for the production of various cancers (Morimoto et al., 1995; Konishi et al., 1985), but it is mainly for green chlorella extract, and specific skin protection effect or skin anti-inflammatory effect for yellow chlorella extract is not known.
일 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 화장료 조성물을 제공하는 것이다. One aspect is to provide a cosmetic composition comprising a yellow chlorella extract and at least one saccharide selected from the group consisting of glucose, oligosaccharide, and fructose.
다른 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 피부 상태의 예방, 개선 또는 치료용 피부외용제 조성물을 제공하는 것이다. Another aspect is to provide a composition for external application for skin for preventing, improving, or treating skin conditions, which includes a yellow chlorella extract and one or more saccharides selected from the group consisting of glucose, oligosaccharide, and fructose.
또 다른 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다. Another aspect is to provide a pharmaceutical composition for preventing or treating an inflammatory disease comprising a yellow chlorella extract and one or more saccharides selected from the group consisting of glucose, oligosaccharide, and fructose.
또 다른 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 피부 상태 개선용 건강기능식품 건강기능식품을 제공하는 것이다. Another aspect is to provide a health functional food for improving skin condition comprising yellow chlorella extract and one or more saccharides selected from the group consisting of glucose, oligosaccharide, and fructose.
일 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 화장료 조성물을 제공한다.One aspect provides a cosmetic composition comprising a yellow chlorella extract and at least one saccharide selected from the group consisting of glucose, oligosaccharide, and fructose.
일 양상에 따른 화장료 조성물은 종래 사용된 녹색 클로렐라 조성물 보다 같은 용량에서 피부 내 보습효과가 더 뛰어난 것을 확인한 황색 클로렐라 추출물을(실시예 1) 화장료 조성물 내 포함시키고, 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 더 포함시켜 피부 세포에서 히알루론산 합성 효소(HAS3), 각질형성 세포 분화 유전자인 FLG 유전자의 발현을 증가시켜 피부에 보습효과 및 피부 장벽 개선 효과가 나타나며, 염증 사이토카인 IL-1β 발현을 현저하게 감소시켜 피부 세포에서 항염증 효과를 나타내는 것을 구체적으로 확인하였다(실험예 1 내지 4). The cosmetic composition according to an aspect contains a yellow chlorella extract (Example 1), which has been confirmed to have a superior moisturizing effect on the skin at the same dose than the conventionally used green chlorella composition, in the cosmetic composition, and includes glucose, oligosaccharide, and fructose. By further including one or more saccharides selected from It was specifically confirmed that -1β expression was significantly reduced to exhibit an anti-inflammatory effect in skin cells (Experimental Examples 1 to 4).
상기 황색 클로렐라 추출물은 조성물 총 중량에 대하여 예를 들면, 1 내지 30중량%, 5 내지 30중량%, 5 내지 45중량%, 5 내지 50중량%, 7 내지 35 중량%, 7 내지 25중량%, 또는 10 내지 20중량%로 포함될 수 있다.The yellow chlorella extract is, for example, 1 to 30% by weight, 5 to 30% by weight, 5 to 45% by weight, 5 to 50% by weight, 7 to 35% by weight, 7 to 25% by weight based on the total weight of the composition, Or 10 to 20% by weight may be included.
상기 당류는 조성물 총 중량에 대하여 예를 들면, 35 내지 80중량%, 40 내지 75중량%, 40 내지 70중량%, 40 내지 65중량%, 45 내지 60 중량%, 또는50 내지 60중량%로 포함될 수 있다. 상기 당류는 보습의 측면에서 조성물 총 중량에 대하여40중량% 이상으로 포함될 수 있고, 조성물의 안정도 측면에서 조성물 총 중량에 대하여 70중량%이하일 수 있다.The sugar may be included in, for example, 35 to 80% by weight, 40 to 75% by weight, 40 to 70% by weight, 40 to 65% by weight, 45 to 60% by weight, or 50 to 60% by weight based on the total weight of the composition. can The sugar may be included in an amount of 40% by weight or more based on the total weight of the composition in terms of moisturizing, and may be included in an amount of 70% by weight or less based on the total weight of the composition in terms of stability of the composition.
상기 조성물 내 포함된 당류는 포도당, 올리고당 및 과당을 예를 들면, 1: 0.1 내지 3: 0.1 내지 3의 중량비, 0.5 내지 2 : 0.5 내지 2의 중량비 또는 1: 0.5 내지 1.5: 0.5 내지 1.5 중량비, 또는 1: 0.5 내지 1: 0.5 내지 1의 중량비로 포함할 수 있다. The saccharides contained in the composition include glucose, oligosaccharide and fructose, for example, in a weight ratio of 1: 0.1 to 3: 0.1 to 3, 0.5 to 2: 0.5 to 2, or 1: 0.5 to 1.5: 0.5 to 1.5 by weight, Alternatively, it may be included in a weight ratio of 1: 0.5 to 1: 0.5 to 1.
또한 상기 조성물은 예를 들면 황색 클로렐라 추출물을 5 내지 30 중량%, 또는 10 내지 25중량%, 또는 10 내지 20 중량%로 포함할 수 있으며, 포도당을 예를 들면 15 내지 30 중량%, 15 내지 25중량% 또는 20 내지 25중량%로 포함할 수 있으며, 올리고당을 예를 들면 10 내지 30 중량%, 10 내지 25중량%, 또는 10 내지 20중량%로 포함할 수 있고, 과당을 예를 들면5 내지 15 중량%, 5 내지 10중량% 또는 10 내지 15중량%로 포함할 수 있다.In addition, the composition may include, for example, 5 to 30% by weight of yellow chlorella extract, or 10 to 25% by weight, or 10 to 20% by weight, and 15 to 30% by weight of glucose, 15 to 25% by weight, for example. It may contain in weight % or 20 to 25% by weight, and may include, for example, 10 to 30% by weight of oligosaccharide, 10 to 25% by weight, or 10 to 20% by weight of oligosaccharide, and 5 to 20% by weight of fructose. 15% by weight, 5 to 10% by weight or 10 to 15% by weight may be included.
상기 조성물은 피부 보습용, 피부 장벽 강화용, 피부 손상 예방 또는 개선용, 또는 피부 염증 예방 또는 개선용일 수 있으며, 상기 조성물은 피부 세포의 HAS3, FLA, Aquaporin3, 및 Claudin1 유전자의 발현을 증가시키고, 인터류킨-1β의 발현을 억제시킬 수 있다. The composition may be for skin moisturizing, skin barrier strengthening, skin damage prevention or improvement, or skin inflammation prevention or improvement, wherein the composition increases the expression of HAS3, FLA, Aquaporin3, and Claudin1 genes in skin cells, It can inhibit the expression of interleukin-1β.
상기 조성물은 예를 들면 화장수, 세럼, 에센스, 로션, 크림, 파우더, 파운데이션, 팩, 패치, 마스크 시트, 젤 연고, 영양크림 및 앰플 중 어느 하나의 제형일 수 있다.The composition may be, for example, in the form of a lotion, serum, essence, lotion, cream, powder, foundation, pack, patch, mask sheet, gel ointment, nourishing cream, and ampoule.
상기 화장료 조성물에는 본 명세서에 개시된 유효성분 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있으며, 통상적으로 사용되는 항산화제, 안정화제, 용해화제, 비타민, 안료, 향료 등과 같은 통상적인 보조제 및 담체를 더 포함할 수 있다. 예를 들어, 상기 화장료 조성물에는 글리세린, 부틸렌글리콜, 폴리옥시에칠렌 경화피마자유, 토코페릴 아세테이트, 시트릭산, 스쿠알란, 소듐 시트레이트, 알란토인 등의 보조성분이 추가로 더 포함될 수 있고, 용제로는 헥산디올, 정제수 등을 포함할 수 있다. 또한 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다. 이외에 포함되는 배합 성분으로서는 유지 성분, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.The cosmetic composition may further include functional additives and components included in general cosmetic compositions in addition to the active ingredients disclosed herein, and conventionally used antioxidants, stabilizers, solubilizers, vitamins, pigments, fragrances, etc. It may further include adjuvants and carriers. For example, the cosmetic composition may further include auxiliary components such as glycerin, butylene glycol, polyoxyethylene hydrogenated castor oil, tocopheryl acetate, citric acid, squalane, sodium citrate, allantoin, and the like, and the solvent includes It may include hexanediol, purified water, and the like. In addition, the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extract. Other ingredients included include oils and fats, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, alcohols, pigments, fragrances, blood circulation promoters, cooling agents, limiting agents (制汗) agent, purified water, etc. are mentioned.
당업자는 본 명세서에 따른 조성물의 유리한 특성이 예상된 첨가에 의해 악영향을 받지 않거나 실질적으로 받지 않도록, 임의의 추가 성분 및/또는 이의 양을 선택할 수 있다. 상기 추가 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 약 0.001 내지 약 30 중량%, 구체적으로 약 0.01 내지 약 25 중량%일 수 있다.A person skilled in the art can select any additional ingredients and/or amounts thereof such that the advantageous properties of the composition according to the present disclosure are not adversely or substantially not adversely affected by the expected addition. The blending amount of the additional component can be easily selected by a person skilled in the art within a range that does not impair the purpose and effect of the present invention, and the blending amount is from about 0.001 to about 30% by weight, specifically from about 0.01 to about, based on the total weight of the composition. 25% by weight.
또한, 각 제형의 화장료 조성물에 있어서 화장료의 제형 또는 사용 목적에 따라 적절한 성분들을 선정하여 배합할 수 있다. 배합 성분 및 방법은 통상의 기술에 따를 수 있으므로 그 구체적인 설명은 본 명세서에서 생략한다.In addition, in the cosmetic composition of each formulation, appropriate ingredients may be selected and formulated according to the formulation or purpose of use of the cosmetic. Since the compounding component and method may follow conventional techniques, a detailed description thereof will be omitted herein.
다른 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 피부 상태의 예방, 개선 또는 치료용 피부외용제 조성물을 제공한다. Another aspect provides a composition for external application for skin for preventing, improving or treating a skin condition comprising a yellow chlorella extract and at least one saccharide selected from the group consisting of glucose, oligosaccharide, and fructose.
상기 상기 피부 상태는 피부 상처, 피부염, 아토피 피부염, 소양증, 습진성 피부질환, 건성 습진, 홍반, 두드러기, 건선, 약발진, 및 여드름으로 이루어진 군으로부터 선택된 어느 하나 이상일 수 있다. The skin condition may be any one or more selected from the group consisting of skin wounds, dermatitis, atopic dermatitis, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, weak rash, and acne.
용어 "치료 또는 개선"은 질환, 장애, 상태 또는 병태, 또는 그의 하나 이상의 증상의 경감, 진행 억제 또는 예방을 지칭하거나, 그를 포함하며, "유효성분" 또는 "약제학적 유효량"은 질환, 장애, 상태 또는 병태, 또는 그의 하나 이상의 증상의 경감, 진행 억제 또는 예방에 충분한 본원에서 제공되는 발명을 실시하는 과정에서 이용되는 조성물의 임의의 양을 의미할 수 있다. 상기 유효량(또는 투여량)은 0.0001mg 내지 10,000mg, 0.001mg 내지 1000mg, 1.0mg 내지 100mg, 0.01mg 내지 1000mg, 0.01mg 내지 100mg, 0.01mg 내지 10mg, 또는 0.01mg 내지 1mg일 수 있다.The term "treatment or amelioration" refers to or includes alleviation, progression inhibition or prevention of a disease, disorder, condition or condition, or one or more symptoms thereof, and "active ingredient" or "pharmaceutically effective amount" refers to a disease, disorder, may mean any amount of a composition utilized in the practice of the invention provided herein sufficient to alleviate, inhibit the progression or prevent the condition or condition, or one or more symptoms thereof. The effective amount (or dosage) may be 0.0001 mg to 10,000 mg, 0.001 mg to 1000 mg, 1.0 mg to 100 mg, 0.01 mg to 1000 mg, 0.01 mg to 100 mg, 0.01 mg to 10 mg, or 0.01 mg to 1 mg.
상기 피부 상태 또는 피부와 관련된 상태의 예는, 피부 노화, 피부 광노화, 상처, 피부염, 아토피 피부염, 소양증, 습진성 피부질환, 건성 습진, 홍반, 두드러기, 건선, 약발진, 또는 여드름, 구진인설질환, 곤충 및 기생충 매개 질환, 표재성 피부 진균증, 세균 감염 질환, 바이러스 질환, 성인성 질환, 자가면역 수포성 질환, 결체조직 질환, 색소이상증, 색소성 건피증 등을 포함할 수 있다. Examples of the skin condition or skin-related condition include skin aging, skin photoaging, wounds, dermatitis, atopic dermatitis, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, weak rash, or acne, papule scaly disease , insect and parasite-borne diseases, superficial dermatophytosis, bacterial infectious diseases, viral diseases, adult diseases, autoimmune bullous diseases, connective tissue diseases, dyspigmentation, xeroderma pigmentosa, and the like.
상기 피부 손상은 외부의 물리적 손상, 화학 물질, 세균, 곰팡이, 바이러스 등의 침투, 자외선에 대한 노출, 피부의 수분 손실, 노화 등에 의한 주름, 자유라디칼(활성산소) 등에 의한 산화, 피부 색소 침착, 피부 염증, 지루성 피부염, 붉어짐(발적, 홍반), 부종, 태선화, 습진, 소양감(가려움), 및 아토피 피부염 등을 포함하는 피부 조직 또는 세포의 임상적 및 미용적 관점에서의 손상을 포함할 수 있다. The skin damage is external physical damage, penetration of chemicals, bacteria, fungi, viruses, etc., exposure to UV rays, moisture loss of the skin, wrinkles due to aging, oxidation by free radicals (active oxygen), etc., skin pigmentation, from a clinical and cosmetic standpoint, including skin inflammation, seborrheic dermatitis, redness (redness, erythema), edema, lichenification, eczema, pruritus (itchiness), and atopic dermatitis, and the like. .
상기 피부는 얼굴, 손, 팔, 다리, 발, 가슴, 배, 등, 엉덩이, 및 두피를 포함하는 신체의 모든 피부 부위를 포함한다.The skin includes all skin parts of the body including the face, hands, arms, legs, feet, chest, belly, back, buttocks, and scalp.
본 명세서에서, 상기 피부외용제는 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치, 약물 함유 붕대, 로션, 또는 그 조합일 수 있다. 상기 피부외용제는 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 겔제 또는 젤의 형태로 제조되어 사용될 수 있다. 상기 피부외용제는 통상 화장품이나 의약품 등의 피부외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다. 상기 피부외용제는, 에데트산이나트륨, 에데트산삼나트륨, 시트르산나트륨, 폴리인산나트륨, 메타인산나트륨, 글루콘산 등의 금속봉쇄제, 카페인, 탄닌, 벨라파밀, 감초추출물, 글라블리딘, 칼린의 과실의 열수추출물, 각종생약, 아세트산토코페롤, 글리틸리틴산, 트라넥삼산 및 그 유도체 또는 그 염등의 약제, 비타민 C, 아스코르브산인산마그네슘, 아스코르브산글루코시드, 알부틴, 코지산, 글루코스, 프룩토스, 트레할로스 등의 당류등도 적절하게 배합할 수 있다.In the present specification, the external preparation for skin may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermally delivered patch, drug-containing bandage, lotion, or a combination thereof. The external preparation for skin may be prepared and used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. The external preparation for skin is a component usually used in external preparations for skin such as cosmetics or pharmaceuticals, for example, an aqueous component, an oily component, a powder component, alcohol, a moisturizer, a thickener, an ultraviolet absorber, a whitening agent, a preservative, an antioxidant, a surfactant, a fragrance , colorant, various skin nutrients, or a combination thereof may be appropriately formulated as needed. The external preparation for skin includes metal-blocking agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belapamil, licorice extract, glablidine, and kaline. Fruit hot water extracts, various herbal medicines, tocopherol acetate, glitylittic acid, tranexamic acid and derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, Sugars, such as trehalose, etc. can be mix|blended suitably.
또한, 상기 조성물은 의약외품 조성물일 수 있다. In addition, the composition may be a quasi-drug composition.
용어 "의약외품"은 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적으로 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 사람이나 동물의 상태 또는 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품을 의미하며, 피부 외용제 및 개인위생용품도 포함할 수 있다.The term "quasi-drug" refers to textiles, rubber products, or the like, which are used for the purpose of treating, alleviating, treating or preventing diseases of humans or animals, have weak action on the human body or do not directly act on the human body, and are not devices or machines. Articles corresponding to those used for sterilization, insecticidal and similar purposes for the prevention of infection and used for the purpose of diagnosing, treating, alleviating, treating or preventing a human or animal condition or disease It refers to items that are not heavy instruments, machines, or devices, and items used for the purpose of pharmacologically affecting the structure and function of humans or animals, excluding those that are not instruments, machines, or devices. may include
또 다른 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물을 제공한다.Another aspect provides a pharmaceutical composition for preventing or treating an inflammatory disease comprising a yellow chlorella extract and one or more saccharides selected from the group consisting of glucose, oligosaccharide, and fructose.
상기 염증성 질환 또는 염증과 관련된 상태의 예는 피부염, 알레르기, 아토피, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증 및 급성 및 만성 염증 질환을 포함할 수 있다.Examples of the inflammatory disease or condition related to inflammation include dermatitis, allergy, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, May include fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, tendinitis, peritenitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases. have.
상기 약학적 조성물은 약제학적으로 허용가능한 희석제 또는 담체를 추가적으로 포함할 수 있다. 상기 희석제는 유당, 옥수수 전분, 대두유, 미정질 셀룰로오스, 또는 만니톨, 활택제로는 스테아린산 마그네슘, 탈크, 또는 그 조합일 수 있다. 상기 담체는 부형제, 붕해제, 결합제, 활택제, 또는 그 조합일 수 있다. 상기 부형제는 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오즈, 또는 그 조합일 수 있다. 상기 붕해제는 카르복시메틸셀룰로오스 칼슘, 전분글리콜산 나트륨, 무수인산일수소 칼슘, 또는 그 조합일 수 있다. 상기 결합제는 폴리비닐피롤리돈, 저치환도 히드록시프로필셀룰로오즈, 히드록시프로필셀룰로오즈, 또는 그 조합일 수 있다. 상기 활택제는 스테아린산 마그네슘, 이산화규소, 탈크, 또는 그 조합일 수 있다.The pharmaceutical composition may further include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be carboxymethyl cellulose calcium, sodium starch glycolate, anhydrous calcium monohydrogen phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
상기 약학적 조성물은 경구 또는 비경구 투여 제형으로 제형화될 수 있다. 경구 투여 제형은 과립제, 산제, 액제, 정제, 캅셀제, 건조시럽제, 또는 그 조합일 수 있다. 비경구 투여 제형은 주사제일 수 있다.The pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may be granules, powders, solutions, tablets, capsules, dry syrups, or a combination thereof. The parenteral dosage form may be an injection.
또 다른 양상은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류를 포함하는 피부 상태 개선용 건강기능식품 건강기능식품을 제공한다. Another aspect provides a health functional food for improving skin condition comprising a yellow chlorella extract and at least one saccharide selected from the group consisting of glucose, oligosaccharide, and fructose.
상기 건강기능식품 조성물은 황색 클로렐라 추출물 및 포도당, 올리고당, 및 과당으로 이루어진 군으로부터 선택된 1종 이상의 당류 혼합물 단독 또는 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 명세서의 조성물은 원료에 대하여 15 중량부 이하의 양으로 첨가될 수 있다. 상기 건강기능식품의 종류에는 특별한 제한은 없다. 건강기능식품의 종류 중 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 건강식품 조성물은 또한 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제, 또는 그 조합을 함유할 수 있다. 상기 건강기능식품 조성물은 또한, 천연 과일쥬스, 과일쥬스 음료, 야채 음료의 제조를 위한 과육, 또는 그 조합을 함유할 수 있다.The health functional food composition may be used alone or in combination with other foods or food ingredients selected from the group consisting of yellow chlorella extract and glucose, oligosaccharide, and fructose, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prophylactic, health or therapeutic treatment). In general, in the production of food or beverage, the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw material. There is no particular limitation on the type of the health functional food. Among the types of health functional food, the beverage composition may contain various flavoring agents or natural carbohydrates as an additional component like a conventional beverage. The natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumartin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used. The health food composition can also be added to nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonated beverages carbonation agent used, or a combination thereof. The health functional food composition may also contain natural fruit juice, fruit juice beverage, fruit flesh for the production of vegetable beverage, or a combination thereof.
또한, 다른 양상은 유효한 양의 상기한 조성물을 그를 필요로 하는 개체에 처리 또는 투여하는 단계를 포함하는 개체의 상태를 예방, 개선, 또는 치료하는 방법을 제공한다. Another aspect also provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering to the subject in need thereof an effective amount of the composition described above.
상기 개체의 상태 또는 조성물에 대해서는 상술한 바와 동일하다. 상기 개체는 포유동물, 예를 들면, 사람, 소, 말, 돼지, 개, 양, 염소, 또는 고양이일 수 있다.The condition or composition of the subject is the same as described above. The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat.
일 양상에 따른 황색 클로렐라 추출물 및 당류를 포함하는 화장료 조성물에 의하면, 피부 세포에서 히알루론산 합성 효소(HAS3), 각질형성 세포 분화 유전자인 FLG 유전자의 발현을 증가시켜 피부에 보습효과 및 피부 장벽 개선 효과가 나타나며, 염증 사이토카인 IL-1β 발현을 현저하게 감소시켜 피부 손상, 피부 상태, 또는 염증성 질환의 예방, 개선 또는 치료에 유용하게 사용할 수 있는 효과가 있다. According to a cosmetic composition comprising a yellow chlorella extract and saccharides according to an aspect, the expression of hyaluronic acid synthase (HAS3) and FLG gene, which is a keratinocyte differentiation gene, is increased in skin cells, thereby moisturizing the skin and improving the skin barrier. appears, and significantly reduces the expression of the inflammatory cytokine IL-1β, thereby having an effect that can be usefully used for the prevention, improvement or treatment of skin damage, skin condition, or inflammatory disease.
도 1은 녹색 또는 황색 클로렐라 추출물을 접촉시킨 24시간 후 히알루론산 합성 효소(HAS3), 수분 채널(Aquaporin3) 및 세포간 연결 인자(Claudin1)의 유전자 발현을 qRT-PCR을 통해 확인한 도이다(*p < 0.05, **p < 0.01 vs. 음성 대조군).
도 2는 황색 클로렐라 추출물 포함 조성물을 인간 각질형성 세포주 HaCaT에 접촉시킨 24시간 이후 히알루론산 합성 유전자인 HAS3의 발현을 qRT-PCR을 통해 확인한 도이다(**p < 0.01 vs. 음성 대조군).
도 3은 황색 클로렐라 추출물 포함 조성물을 인간 각질형성 세포주 HaCaT에 접촉시킨 24시간 이후 필라그린의 유전자 발현을 qRT-PCR을 통해 확인한 도이다(**p < 0.01 vs. 음성 대조군).
도 4는 황색 클로렐라 추출물 포함 조성물을 염증을 유도한 인간 각질형성 세포주 HaCaT에 접촉시킨 4시간 이후 IL-1β 의 유전자 발현을 qRT-PCR을 통해 확인한 도이다(**p < 0.01 vs. 음성 대조군, ##p < 0.01 vs. 양성 대조군).
도 5은 황색 클로렐라 추출물을 포함한 M2 내지 M2를 피부에 도포한 이후의 피부 수분양을 촬영한 결과(도 5A) 및 피부도포 후의 피부 수분양을 그래프화 한 결과(도 5B)를 나타낸 도이다. 1 is a diagram confirming the gene expression of hyaluronic acid synthase (HAS3), water channel (Aquaporin3), and intercellular linkage factor (Claudin1) through qRT-
2 is a diagram illustrating the expression of HAS3, a hyaluronic acid synthesis gene, through qRT-PCR after 24 hours of contacting a composition containing a yellow chlorella extract with the human keratinocyte line HaCaT (**p < 0.01 vs. negative control).
3 is a diagram illustrating the gene expression of filaggrin through qRT-PCR after 24 hours of contacting a composition containing a yellow chlorella extract with the human keratinocyte line HaCaT (**p < 0.01 vs. negative control).
4 is a diagram confirming the gene expression of IL-1β through qRT-PCR after 4 hours of contacting a composition containing a yellow chlorella extract with the inflammation-induced human keratinocyte line HaCaT (**p < 0.01 vs. negative control, ##p < 0.01 vs. positive control).
FIG. 5 is a diagram showing the results of photographing the skin moisture content after applying M2 to M2 including the yellow chlorella extract to the skin ( FIG. 5A ) and graphing the skin moisture content after skin application ( FIG. 5B ).
이하, 본 발명을 구체적으로 설명하기 위해 실시예 및 실험예를 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예 및 실험예는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실시예 및 실험예에 한정되는 것으로 해석 되어서는 안 된다. 본 발명의 실시예 및 실험예는 당 업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되는 것이다.Hereinafter, examples and experimental examples will be described in detail to explain the present invention in detail. However, the Examples and Experimental Examples according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the Examples and Experimental Examples described below. The Examples and Experimental Examples of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.
실시예 1. 황색 클로렐라 추출물의 보습 효과의 확인Example 1. Confirmation of moisturizing effect of yellow chlorella extract
종래 다수 화장료 조성물에 활용되었던 녹색 클로렐라 대비 황색 클로렐라가 피부 보습 효과가 우수성을 가지는지 여부를 확인하는 실험을 수행하였다. 실험에 사용한 녹색 클로렐라 및 황색 클로렐라 추출물을 대상 주식회사에서 구입하고, 상기 클로렐라 추출물 각각 100ppm을 인간 각질형성 세포주 HaCaT에 접촉시키고, 접촉 24시간 이후의 세포주에서의 세포 내 피부 내 보습에 관여하는 히알루론산 합성 효소(HAS3), 수분 채널(Aquaporin3) 및 세포간 연결 인자(Claudin1) 유전자 발현이 증가하였는지에 관하여 qRT-PCR을 수행하여 유전자 발현 증가를 확인하고, 이를 도 1에 나타내었다. 세포주에 추출물을 미처리한 군을 음성대조군으로 하였다.An experiment was conducted to determine whether yellow chlorella had superior skin moisturizing effect compared to green chlorella used in a number of conventional cosmetic compositions. The green chlorella and yellow chlorella extracts used in the experiment were purchased from Daesang Co., Ltd., and 100 ppm of each of the chlorella extracts was contacted with the human keratinocyte line HaCaT, and hyaluronic acid involved in intracellular moisturizing in the
도 1에 나타난 바와 같이, 음성 대조군 대비 녹색 클로렐라 추출물을 처리한 경우, 평균적으로 1.2배 정도 발현이 상승하여 피부 보습 유전자들의 발현이 다소 상승한 것을 확인할 수 있었다. 이에 반해 황색 클로렐라 추출물을 처리한 경우 평균적으로 2배 정도 보습 유전자가 유의하게 상승한 것을 확인하였다. 따라서, 녹색 클로렐라 대비 황색 클로렐라 추출물이 피부의 보습에 관여하는 유전자 들의 발현을 모두 상승시키므로 우수한 보습 효과를 나타낼 수 있음을 확인할 수 있었다. As shown in FIG. 1 , when the green chlorella extract was treated compared to the negative control, the expression of the skin moisturizing genes increased by about 1.2 times on average, and it was confirmed that the expression of the skin moisturizing genes was slightly increased. On the other hand, when the yellow chlorella extract was treated, it was confirmed that the moisturizing gene was significantly increased by about 2 times on average. Therefore, compared to green chlorella, it was confirmed that the yellow chlorella extract increased the expression of all genes involved in skin moisturizing, so that it could exhibit an excellent moisturizing effect.
실시예 2. 황색 클로렐라 추출물 포함 조성물의 제조Example 2. Preparation of a composition comprising yellow chlorella extract
상기 실시예 1에서 우수한 보습 효과를 확인한 황색 클로렐라 추출물을 포함하는 화장료 조성물 중 특히 우수한 보습 및 피부 항염 효과가 나타나는 조성물을 찾아내기 위하여 황색 클로렐라 추출물과 포도당, 올리고당 및 과당을 포함하는 당을 조성물 내 각각 비율을 달리하여 첨가시키고, 조성물을 제조하였다. 각각의 조성물의 함량을 하기 표 1에 나타내었다. In order to find a composition showing particularly excellent moisturizing and anti-inflammatory effects on the skin among the cosmetic compositions containing the yellow chlorella extract, which was confirmed to have an excellent moisturizing effect in Example 1, a yellow chlorella extract and a sugar containing glucose, oligosaccharide and fructose were added in the composition, respectively. They were added in different proportions, and a composition was prepared. The content of each composition is shown in Table 1 below.
(함수결정포도당)glucose
(hydrous crystalline glucose)
(HFSS 55)fruit sugar
(HFSS 55)
(AlgaRich Vegi-P55 )Yellow Chlorella Extract
(AlgaRich Vegi-P55)
실험예 1. 황색 클로렐라 추출물 포함 조성물의 수분 개선 효과의 확인Experimental Example 1. Confirmation of the moisture improvement effect of the composition containing the yellow chlorella extract
황색 클로렐라 추출물을 피부에 처리하는 경우 히아루론산 합성능을 증가시켜 수분 개선능을 증가시키는지 확인하기 위한 실험을 수행하였다. 인간 각질형성 세포주 HaCaT에 실시예 2에서 제조한 조성물 각각 0.001%, 대략 8ppm을 접촉시키고, 접촉 24시간 이후의 히알루론산 합성 유전자 HAS3에 대한 qRT-PCR을 수행하여 HAS3 유전자 발현 증가를 확인하고, 이를 도 2에 나타내었다. 세포주에 추출물을 미처리한 군을 음성 대조군으로 하고, 히알루론 산(Hyaruronic acid: HA) 10ppm을 접촉시킨 군을 양성 대조군으로 하였다. When the yellow chlorella extract was treated on the skin, an experiment was performed to confirm whether the moisture improvement ability was increased by increasing the hyaluronic acid synthesis ability. The human keratinocyte cell line HaCaT was contacted with 0.001%, approximately 8 ppm, respectively, of the composition prepared in Example 2, and qRT-PCR was performed on the hyaluronic acid
도 2에 나타한 바와 같이, 음성 대조군 대비 M2 내지 M4는 유의적인 히알루론산 합성 유전자 HAS3의 발현 증가가 확인되었다. 특히, M3은 양성 대조군 대비 약 2배정도 발현 상승을 확인하였고, M2 및 M4는 평균 3배정도의 발현 상승을 확인할 수 있었다. 따라서, 황색 클로렐라 추출물과 특정 비율로 포도당, 올리고당 및 과당이 혼합된 당 혼합물을 처리하는 경우 피부의 보습에 관여하는 유전자인 HAS3의 발현을 유의하게 증가시키므로 우수한 보습 효과가 나타날 수 있음을 확인하였다. As shown in FIG. 2 , a significant increase in expression of the hyaluronic acid synthesis gene HAS3 was confirmed in M2 to M4 compared to the negative control group. In particular, M3 was confirmed to have an expression increase of about 2-fold compared to the positive control group, and M2 and M4 were confirmed to have an average expression increase of about 3-fold. Therefore, it was confirmed that, when the yellow chlorella extract and the sugar mixture containing glucose, oligosaccharide and fructose in a specific ratio were treated, the expression of HAS3, a gene involved in moisturizing the skin, was significantly increased, so that an excellent moisturizing effect could be obtained.
실험예 2. 황색 클로렐라 추출물 포함 조성물의 피부 장벽 개선 효과의 확인Experimental Example 2. Confirmation of skin barrier improvement effect of a composition containing yellow chlorella extract
황색 클로렐라 추출물을 피부에 처리하는 경우 피부 분화를 유도하여 피부 장벽 개선능을 증가시키는지 확인하기 위한 실험을 수행하였다. 인간 각질형성 세포주 HaCaT에 실시예 2에서 제조한 조성물 각각 0.001%, 대략 8ppm을 접촉시키고, 접촉 24시간 이후의 필라그린(filaggrin : FLG) 유전자에 대한 qRT-PCR을 수행하여 유전자 발현 증가를 확인하고, 이를 도 3에 나타내었다. 세포주에 추출물을 미처리한 군을 음성대조군으로 하였다. When the yellow chlorella extract was treated on the skin, an experiment was performed to determine whether the skin barrier improvement ability was increased by inducing skin differentiation. The human keratinocyte cell line HaCaT was contacted with each of 0.001%, approximately 8 ppm of the composition prepared in Example 2, and qRT-PCR for the filaggrin (FLG)
도 3에 나타난 바와 같이, 음성 대조군 대비 M2 내지 M4에서는 유의적인 각질형성 세포 분화 유전자인 FLG의 발현 증가가 확인되었다. 특히, M2은 음성 대조군 대비 약 6배정도 발현 상승을 확인하였고, M3는 평균 10배정도의 발현 상승을 확인할 수 있었다. 따라서, 황색 클로렐라 추출물과 특정 비율로 포도당, 올리고당 및 과당이 혼합된 당 혼합물을 처리하는 경우 각질형성 세포 분화 유전자인 FLG 의 발현을 유의하게 증가시키므로 우수한 피부 장벽 개선 효과가 나타날 수 있음을 확인하였다. As shown in FIG. 3 , a significant increase in the expression of FLG, a keratinocyte differentiation gene, was confirmed in M2 to M4 compared to the negative control group. In particular, M2 was confirmed to have an expression increase of about 6 times compared to the negative control group, and M3 was confirmed to have an average expression increase of about 10 times. Therefore, it was confirmed that, when the yellow chlorella extract and the sugar mixture in which glucose, oligosaccharide and fructose were mixed in a specific ratio were treated, the expression of FLG, a keratinocyte differentiation gene, was significantly increased, so that an excellent skin barrier improvement effect could appear.
실험예 3. 황색 클로렐라 추출물 포함 조성물의 피부 염증 개선 효과의 확인Experimental Example 3. Confirmation of skin inflammation improvement effect of yellow chlorella extract-containing composition
황색 클로렐라 추출물을 피부에 처리하는 경우 피부 염증을 유도하는 인터류킨-1β(IL-1β)의 발현을 저해하여 피부 염증 개선시키는지 확인하기 위한 실험을 수행하였다. 인간 각질형성 세포주 HaCaT에 10 μg/ml의 폴리이노신산 폴리시티딜산혼성중합체(Polyinosinic:polycytidylic acid : Poly I:C)와 10 ng/ml 의 인터류킨-4(IL-4)을 처리하여 염증을 유도한 이후, 실시예 2에서 제조한 조성물 각각 0.001%, 대략 8ppm을 접촉시키고, 접촉 4시간 이후의 인터류킨-1β에 대한 qRT-PCR을 수행하여 유전자 발현 증가를 확인하고, 이를 도 4에 나타내었다. 세포주에 추출물을 미처리한 군을 음성 대조군으로 하였고, 항염효과를 나타내는 1μM의 덱사메타손을 처리한 군을 양성 대조군으로 하였다. When the yellow chlorella extract was treated on the skin, an experiment was performed to determine whether the skin inflammation was improved by inhibiting the expression of interleukin-1β (IL-1β), which induces skin inflammation. Inflammation was induced by treating the human keratinocyte line HaCaT with 10 μg/ml of polyinosinic acid polycytidylic acid (Poly I:C) and 10 ng/ml of interleukin-4 (IL-4). Thereafter, each of the compositions prepared in Example 2 was brought into contact with 0.001%, approximately 8 ppm, and qRT-PCR was performed on interleukin-
도 4에 나타난 바와 같이, 음성 대조군 대비 염증을 유도한 군에서는 IL-1β 의 발현이 5배정도 증가한 것을 확인하였다. 이에 M2 조성물을 처리한 군은 항염효과를 나타내는 양성 대조군인 덱사메타손을 처리한 군과 비슷한 정도의 항염효과를 나타내는 것을 확인하였다. 특히 M3 조성물은 처리한 경우, 최대 60%이상의 염증 개선 효과가 나타나는 것을 확인하였고, 이는 덱사메타손 보다도 현저한 염증 개선 효과를 나타내는 것임을 확인하였다. 따라서, 황색 클로렐라 추출물과 특정 비율로 포도당, 올리고당 및 과당이 혼합된 당 혼합물을 처리하는 경우 피부 세포 내 IL-1β 의 발현을 유의하게 억제시켜 우수한 항염 효과를 나타낼 수 있음을 확인하였다.As shown in FIG. 4 , it was confirmed that the expression of IL-1β was increased by about 5 times in the group inducing inflammation compared to the negative control group. Accordingly, it was confirmed that the group treated with the M2 composition exhibited an anti-inflammatory effect similar to that of the group treated with dexamethasone, which is a positive control group showing an anti-inflammatory effect. In particular, when the M3 composition was treated, it was confirmed that an inflammatory improvement effect of up to 60% or more appeared, and it was confirmed that it exhibits a more significant inflammatory improvement effect than dexamethasone. Therefore, it was confirmed that when the yellow chlorella extract and the sugar mixture in which glucose, oligosaccharide, and fructose were mixed in a specific ratio were treated, the expression of IL-1β in skin cells was significantly suppressed to exhibit excellent anti-inflammatory effect.
실험예 4. 황색 클로렐라 추출물 포함 조성물의 Experimental Example 4. Composition of yellow chlorella extract in vivoin vivo 에서 피부 보습 개선 효과의 확인confirmation of skin moisturizing improvement effect in
황색 클로렐라 추출물을 피부에 처리하는 경우 피부 내 수분 양을 유지시켜 보습을 실제적으로 유도하는지 확인하기 위한 임상실험을 수행하였다. 평균 나이 25.6세의 성인 5명을 대상으로, 실제적인 실시예 2에서 우수한 보습 효과를 나타낸 M2 내지 M2를 팔에 100 μl 도포하고 8시간 이후 Biox epsilon (Biox Systems Ltd, England)을 사용하여, 팔 피부의 수분 양을 촬영한 결과를 도 5A에 도포 후의 피부수분양을 그래프화 한 결과를 도 5B에 나타내었다. 히알루론산 500ppm을 처리한 군을 양성 대조군으로 사용하였고, 조성물 미처리군을 음성 대조군으로 하였다.When the yellow chlorella extract is treated on the skin, a clinical experiment was performed to confirm that moisture is actually induced by maintaining the amount of moisture in the skin. For 5 adults with an average age of 25.6 years, 100 μl of M2 to M2, which showed an excellent moisturizing effect in Practical Example 2, was applied to the arm, and after 8 hours, using Biox epsilon (Biox Systems Ltd, England), The result of photographing the amount of moisture in the skin is shown in FIG. 5A, and the result of graphing the amount of moisture in the skin after application is shown in FIG. 5B. A group treated with 500 ppm of hyaluronic acid was used as a positive control group, and a group untreated with the composition was used as a negative control group.
상기 도 5A 및 5B에서 확인한 바와 같이, 피부 수분양이 많은 경우 밝게 표시되는 바, M2 내지 M4 조성물을 처리한 경우 피부 수분도가 음성대조군 대비 유의할 정도의 수분 증가를 확인할 수 있었다. 특히 M2 및 M3을 도포한 경우, 도포 이후의 피부 내 함유된 수분 양이 많은 것을 확인할 수 있었으며, 또한 M4을 도포한 경우에서도 양성 대조군과 비슷한 정도의 피부 수분도가 나타나는 것을 확인하였다. 따라서, 황색 클로렐라 추출물과 특정 비율로 포도당, 올리고당 및 과당이 혼합된 당 혼합물을 처리하는 경우 실제적으로 피부에 도포되는 경우에 있어서도 피부 보습 효과가 우수하게 나타나는 것을 확인할 수 있었다.As confirmed in FIGS. 5A and 5B, when the amount of skin moisture is high, it is displayed brightly, and when the M2 to M4 compositions are treated, it can be confirmed that the moisture level of the skin is significantly increased compared to the negative control group. In particular, when M2 and M3 were applied, it was confirmed that the amount of moisture contained in the skin after application was large, and also when M4 was applied, it was confirmed that the skin moisture level similar to that of the positive control group appeared. Therefore, when the yellow chlorella extract and the sugar mixture in which glucose, oligosaccharide and fructose were mixed in a specific ratio were treated, it was confirmed that the skin moisturizing effect was excellent even when actually applied to the skin.
Claims (13)
포도당, 올리고당, 및 과당을 포함하는 당류;를 포함하는 화장료 조성물로서,
조성물 총 중량에 대하여 황색 클로렐라 추출물은 5 내지 30 중량%, 포도당은 10 내지 30 중량%, 올리고당은 10 내지 30 중량% 및 과당은 15 내지 20 중량%로 포함되는 것인 화장료 조성물.Yellow Chlorella (chlorella) extract; and
A cosmetic composition comprising; sugars including glucose, oligosaccharides, and fructose,
A cosmetic composition comprising 5 to 30% by weight of yellow chlorella extract, 10 to 30% by weight of glucose, 10 to 30% by weight of oligosaccharides, and 15 to 20% by weight of fructose, based on the total weight of the composition.
포도당, 올리고당, 및 과당을 포함하는 당류;를 포함하는 피부 상태의 예방, 개선 또는 치료용 피부 외용제 조성물로서,
조성물 총 중량에 대하여 황색 클로렐라 추출물은 5 내지 30 중량%, 포도당은 10 내지 30 중량%, 올리고당은 10 내지 30 중량% 및 과당은 15 내지 20 중량%로 포함되는 것인 피부 외용제 조성물. Yellow Chlorella (chlorella) extract; and
A composition for topical application to the skin for preventing, improving or treating skin conditions, including saccharides including glucose, oligosaccharides, and fructose,
The composition for external application for skin that contains 5 to 30% by weight of yellow chlorella extract, 10 to 30% by weight of glucose, 10 to 30% by weight of oligosaccharide, and 15 to 20% by weight of fructose, based on the total weight of the composition.
포도당, 올리고당, 및 과당을 포함하는 당류;를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물로서,
조성물 총 중량에 대하여 황색 클로렐라 추출물은 5 내지 30 중량%, 포도당은 10 내지 30 중량%, 올리고당은 10 내지 30 중량% 및 과당은 15 내지 20 중량%로 포함되는 것인 약학적 조성물.Yellow Chlorella (chlorella) extract; and
As a pharmaceutical composition for the prevention or treatment of inflammatory diseases, including; glucose, oligosaccharides, and sugars including fructose,
A pharmaceutical composition comprising 5 to 30% by weight of yellow chlorella extract, 10 to 30% by weight of glucose, 10 to 30% by weight of oligosaccharides, and 15 to 20% by weight of fructose, based on the total weight of the composition.
포도당, 올리고당, 및 과당을 포함하는 당류;를 포함하는 피부 상태 개선용 건강기능식품로서,
건강기능식품 총 중량에 대하여 황색 클로렐라 추출물은 5 내지 30 중량%, 포도당은 10 내지 30 중량%, 올리고당은 10 내지 30 중량% 및 과당은 15 내지 20 중량%로 포함되는 것인 피부 상태 개선용 건강기능식품.Yellow Chlorella (chlorella) extract; and
As a health functional food for improving skin condition, including; sugars including glucose, oligosaccharides, and fructose,
Based on the total weight of the health functional food, yellow chlorella extract is contained in 5 to 30% by weight, glucose is 10 to 30% by weight, oligosaccharide is 10 to 30% by weight, and fructose is 15 to 20% by weight. Health for improving skin condition functional food.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190164068A KR102337919B1 (en) | 2019-12-10 | 2019-12-10 | Cosmetic composition containing yellow chlorella extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190164068A KR102337919B1 (en) | 2019-12-10 | 2019-12-10 | Cosmetic composition containing yellow chlorella extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210073697A KR20210073697A (en) | 2021-06-21 |
KR102337919B1 true KR102337919B1 (en) | 2021-12-13 |
Family
ID=76600108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190164068A KR102337919B1 (en) | 2019-12-10 | 2019-12-10 | Cosmetic composition containing yellow chlorella extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102337919B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240028824A (en) | 2022-08-25 | 2024-03-05 | 에이치케이이노엔 주식회사 | Compositions containing Nypa fruticans extract for the prevention, alleviation, or treatment of inflammatory gastrointestinal disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3573941B2 (en) * | 1998-02-13 | 2004-10-06 | マイクロアルジェコーポレーション株式会社 | Composition having hyaluronidase inhibitory activity and cosmetic containing the composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930003117A (en) * | 1991-07-19 | 1993-02-24 | 강진구 | Mode automatic switching method and device of VTR system |
KR100523241B1 (en) * | 2003-03-28 | 2005-10-24 | 학교법인 인제학원 | Cosmetic composition comprising an extract of Chlorella having anti-inflammatory activity |
KR102114444B1 (en) * | 2017-02-03 | 2020-05-21 | 정호철 | Composition for preventing or improving diseases associated with inflammation containing glucose |
-
2019
- 2019-12-10 KR KR1020190164068A patent/KR102337919B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3573941B2 (en) * | 1998-02-13 | 2004-10-06 | マイクロアルジェコーポレーション株式会社 | Composition having hyaluronidase inhibitory activity and cosmetic containing the composition |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240028824A (en) | 2022-08-25 | 2024-03-05 | 에이치케이이노엔 주식회사 | Compositions containing Nypa fruticans extract for the prevention, alleviation, or treatment of inflammatory gastrointestinal disease |
Also Published As
Publication number | Publication date |
---|---|
KR20210073697A (en) | 2021-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100812596B1 (en) | Compositions comprising compounds of natural origin for damaged skin | |
JP2018524400A (en) | Petrolatum-based delivery system for active ingredients | |
WO2008140200A1 (en) | External compositions for the skin | |
KR100795512B1 (en) | Skin care composition comprising the extract of Centella asiatica and Magnolia kobus | |
EP2630961B1 (en) | Agent for promoting healing of a wound of a living body | |
KR101937345B1 (en) | A composition for anti-bacterial effect and anti-inflammation comprising unripe apple extracts and baicalin | |
KR20190014774A (en) | Atopic dermatitis remedy and method for producing the same | |
KR101225114B1 (en) | Composition for whitenings and treating skin damage or disease comprising bee venom | |
CN107670027B (en) | Compositions and methods for treating skin conditions | |
KR102072948B1 (en) | Pharmaceutical Fermented composition for treatment of wound | |
WO2011115061A1 (en) | Hyaluronic acid production promoter | |
KR102337919B1 (en) | Cosmetic composition containing yellow chlorella extract | |
KR100668290B1 (en) | Cosmeceutical compositions comprising a Rumex acetosella L. extract and/or a Rheum coreanum extract with improvement effect of atopic dermatitis | |
KR20230120619A (en) | Composition for improving skin conditions | |
KR102176883B1 (en) | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin | |
KR102273234B1 (en) | Kocuria varians strain and skin condition improving uses of thereof | |
KR101736503B1 (en) | Elastase inhibitor | |
KR102249432B1 (en) | Composition for preventing or treating skin inflammation comprising Cocos nucifera extract | |
KR101681026B1 (en) | Manufacturing method of allergen removed water soluble royal jelly and use thereof | |
KR102488864B1 (en) | Composition Containing Terminalia Chebula Extract and Artemisia Extract for Controlling Skin Bacterial Flora Growth, or Enhancing Skin Immunity | |
KR102507175B1 (en) | Antimicrobial cosmetic composition comprising Salvia Officinalis extract, Caesalpinia Sappan Bark Extract, Houttuynia cordata Extract, Rosmarinus Officinalis Extract, Allium scorodorpasum Extract, and Coptis Chinensis Root Extract as active ingredients | |
KR102650364B1 (en) | Composition for anti-oxidation, anti-inflammation, anti-atopy, anti-wrinkle and improvement of moisturizing comprising extract of Lycorisradiata | |
KR102416652B1 (en) | Cosmetic composition for anti-irritation due to the particulate matter and improving skin conditions | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
KR20130073040A (en) | A composition comprising hemistepsin a or b isolated from the extract of hemistepita lyrata bunge for preventing and treating dandruff |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |